Algo version: 0.98b
Human Metabolome is listed at the JPX Exchange
Human Metabolome [6090.T]
JPX Sector: Healthcare Industry:Medical Diagnostics Research

Is Human Metabolome stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Human Metabolome pays dividends. Last time was Thursday 1st of January 1970 where the investors holding the stock on Friday 27th of June 2025 were paid JPY0 per share. Over the last 3 times between 2023 and 2025, Human Metabolome has paid JPY25 with an average of JPY8.33 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Human Metabolome 10 years ago, but if you had invested on Friday 22nd of November 2019 when the price was JPY819.00, you would have made a loss of JPY-215.00 per share or -26.25%

Yes, the average daily trading liquidity for Human Metabolome is JPY4 652 thousand. You should therefore be able to get in and out of your positions relatively fast.

Human Metabolome has little of the business financed by loans. This puts the company at lower risk in periods of high inflation where borrowing costs usually go up. Human Metabolome has a good net profit margin of 18.08% and should have high tolerances against inflation.

We have calculated the inflation risk for Human Metabolome to be low [0.4 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.